Immune health requires innate and adaptive immune cells to engage precisely balanced pro-and anti-inflammatory forces. A holistic understanding of how individual small molecules affect this balance is essential to anticipate immune-related side effects, select mitigating immunomodulatory therapies and highlight novel utility as immunomodulators. We previously showed that the high-specificity, low-toxicity cyclin dependent kinase 8 (CDK8) inhibitor DCA promotes tolerogenic effects in innate immune cells. Here, we demonstrate that DCA exerts a novel profile of tolerogenic activity on CD4 + T cells, promoting Treg and Th2 while inhibiting Th1 and Th17 differentiation. DCA enhances human Treg differentiation and our models demonstrate clear tolerogenic function of DCA-driven Tregs in the absence of confounding contribution from DCA-innate immune interactions. DCA engages unique mechanisms, including specifically enhancing early Foxp3 expression via regulating c-Jun phosphorylation, to promote Treg differentiation. CDK8 inhibitors are currently being developed to treat cancer; our findings suggest that the potential blunting of host-versus-tumor effects may warrant ancillary pro-inflammatory agents. Importantly, these results highlight novel utility of DCA as an immunomodulator, not only in vivo, but also in ex vivo cellular therapy.
Introduction
The immune system comprises innate and adaptive immune cells whose collaborative and coordinated responses are required to maintain the healthy state. Each cell type can exert either pro-or anti-inflammatory forces. For example, innate immune cells can secrete either pro-(e.g. IFNg) or anti-(e.g. IL-10) inflammatory cytokines while CD4 + T cells can differentiate into either pro-(e.g. Th1, Th17) or anti-(Treg) inflammatory subsets (1) (2) (3) (4) (5) . These pro-and inflammatory forces must be precisely balanced; dysregulation of this balance can predispose to autoimmunity, infection or cancer (3, 6) . Patients and murine models demonstrate that defects in individual cell types can lead to disease. Therefore, it is important to holistically understand how individual genes and therapies affect both innate and adaptive immune responses. This understanding is essential to restore immune homeostasis in any given patient and to anticipate immunomodulatory side effects of current therapies.
We have previously demonstrated how small molecules can highlight novel pathways of immunoregulation in primary immune cells. For example, we showed that small molecule inhibition of the dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) promotes differentiation of murine and human CD4 + T cells into Tregs (7) . We also showed that small molecule inhibition of salt-induced kinases (SIKs) enhanced production of IL-10 by murine and human myeloid cells (8) . However, a comprehensive understanding of how both innate and adaptive immune cell function is modulated remains lacking for most small molecules.
Here, we investigate the effect of the natural product-derived small molecule dihydrocortistatin A (DCA) on murine and human CD4 + T cells. We previously found that DCA promotes production of IL-10 in myeloid cells by inhibiting cyclin-dependent kinase 8 (CDK8) (9) (10) (11) . CDK8 is an essential component of the CDK8 submodule of the Mediator coactivator complex, which regulates RNA polymerase II activity (12, 13) . The CDK8 submodule facultatively binds the Mediator complex, phosphorylates transcription factors and regulates specific pathways (13) (14) (15) .
CDK8 phosphorylates several transcription factors important in many immune cells, including STAT1 Ser727 , STAT3 Ser727 and the AP-1 family member c-Jun (16) (17) (18) (19) . Consistent with this, growing evidence suggests that CDK8 regulates both innate and adaptive immune responses. We previously showed that c-Jun phosphorylation by CDK8 regulates IL-10 production in innate immune cells (11) . Deletion of CDK8 in NK cells enhances cytotoxicity and improves tumor surveillance (20, 21) . Furthermore, CDK8/19 inhibitors promote Treg differentiation (22, 23) . These findings highlight the importance of better understanding which immune processes are regulated by CDK8 inhibition, and how. In particular, recent studies pointing to DCA as the CDK8 inhibitor with highest specificity and lowest toxicity highlight DCA as a particularly important compound to investigate (24) .
Here, we demonstrate that DCA exerts a unique pattern of immunomodulation compared to other known immunomodulatory small molecules. Using both small molecule inhibitors and CRISPR/Cas9 knockdown, we find that DCA works by disrupting CDK8 to promotes the differentiation of Treg and Th2 cells while inhibiting the differentiation of pro-inflammatory subsets including Th1 and Th17. We show that DCA-driven Tregs are fully suppressive in the absence of concomitant tolerogenic effects on innate immune cells. DCA works through a novel mechanism of enhancing early Foxp3 expression, which our data suggest involves modulation of c-Jun activity. These findings highlight a novel immunomodulatory role for DCA in broadly driving tolerogenic programs in both innate and adaptive immune cells while inhibiting pro-inflammatory programs in CD4 + T cells. These findings are discussed in the context of implications to future therapeutic use of CDK8 inhibitors.
Results

DCA exerts tolerogenic effects on murine and human CD4 + T cell differentiation.
Given our previous observation that DCA promotes tolerogenic IL-10 production in innate immune cells, we determined whether DCA exerts tolerogenic effects on CD4 + T cell differentiation (11) . We tested the effect of DCA on naïve murine CD4 + T cells cultured in suboptimal pro-Treg or -Th2 conditions (Treg low and Th2 low , respectively) as we previously described (7) . DCA enhanced differentiation of both Treg and Th2 cells ( Fig. 1A) . DCA increased Tregs specifically in cultures of FACS-sorted naïve CD4 + T cells, but not sorted Tregs, further demonstrating that the increase in Tregs is due to enhanced differentiation of Tregs rather than expansion of existing Tregs (Supplemental Fig. 1A ). To examine if these tolerogenic effects extended to inhibiting differentiation of pro-inflammatory T cell lineages, we tested how DCA impacts murine T cells cultured in near-optimal pro-Th1 and -Th17 conditions (Th1 hi and Th17 hi , respectively). DCA inhibited differentiation of Th1 and Th17 cells by >50% ( Fig. 1A) . Notably, DCA promoted differentiation of Treg and Th2 cells even in near-optimal Th17 hi and Th1 hi conditions respectively ( Fig. 1A , FACS plots). In the context of non-polarizing Th0 conditions, DCA significantly, albeit modestly, enhanced murine Treg and Th2 differentiation ( Fig. 1B ). Th1 differentiation was slightly reduced below the level of statistical significance and Th17 cells were too infrequent to accurately assess ( Fig. 1B) . These results suggest that DCA can enhance Treg/Th2 differentiation even with very low levels of cytokine that may be present in media (e.g. TGFb) or produced stochastically (e.g. IL-4). Therefore, DCA exerts powerful tolerogenic effects on murine T cell differentiation.
We further investigated whether DCA similarly affects human Treg differentiation by using human CD4 + T cells cultured in suboptimal (human-specific) Treg low conditions. DCA treatment enhanced the total number and percentage of human Tregs, similar to our observations in murine cells ( Fig. 1C-D) . We next sought to benchmark the pro-Treg effect of DCA against the well-described Treg enhancers all-trans retinoic acid (ATRA) and rapamycin (Rapa) (25) (26) (27) (28) (29) (30) (31) . In murine and human CD4 + T cells cultured in suboptimal Treg low conditions, DCA treatment enhanced the total number of Tregs significantly higher than either ATRA or rapamycin (Fig. 1C ). In addition, DCA enhanced the percentage of Tregs to a level similar to ATRA and rapamycin ( Fig. 1D ). These results highlight that DCA potently enhances Treg differentiation in both murine and human T cells.
DCA identifies a novel chemical immunophenotype secondary to CDK8 inhibition. To generate a more holistic view of how DCA impacts T cell differentiation, we investigated the doseresponse of murine CD4 + T cells to DCA and two other tolerogenic small molecules in the context of suboptimal pro-Treg, Th2, Th1 and Th17 conditions (Treg low , Th2 low , Th1 low and Th17 low , respectively) (7) . These experiments showed that DCA enhanced differentiation of both murine Treg and Th2 cells with identical EC50, supporting the involvement of a common mechanistic target ( Fig. 2A ). The EC50 of the pro-Treg effect was similar to the EC50 we previously found for enhancing IL-10 production in bone marrow-derived dendritic cells, suggesting a similar mechanism of action (11) . To understand if compounds that enhance Treg differentiation also typically enhance Th2 differentiation, we tested the DYRK1A inhibitor harmine, which we previously demonstrated to enhance Treg and inhibit Th17, and to a lesser extent Th1, differentiation (7) . Harmine did not enhance differentiation of Th2 cells ( Fig. 2A) . Conversely, to understand if compounds that exert tolerogenic effects on innate immune cells typically enhance Treg and Th2 differentiation, we tested the multi-kinase inhibitor HG-9-91-01 that potently targets salt-inducible kinase (SIK) 1-3, which we previously showed enhances IL-10 production in bone marrow-derived dendritic cells (BMDCs) (8) . Inhibiting SIK1-3 did not enhance differentiation of naïve murine CD4 + T cells towards any Th lineage, consistent with innate cell-specific tolerogenic effects ( Fig. 2A ). Therefore, DCA, HG-9-91-01 and harmine appear to induce distinct immune phenotypic profiles, which we term chemical immunophenotypes, reflecting distinct pathways regulating tolerogenicity in innate and adaptive immune cells.
We and others have previously shown that DCA inhibits CDK8 kinase activity with immunomodulatory effects (11, (20) (21) (22) (23) . We used two different approaches to validate CDK8 as the Treg-relevant mechanistic target of DCA. Firstly, we tested DCA side-by-side with a structurally distinct small molecule CDK8 inhibitor, BRD-6989 (11). In Treg low conditions, both CDK8 inhibitors showed concentration-dependent enhancement of murine Treg differentiation with concentrations that induce half-maximal effects (EC50) for each compound similar to that observed for enhancing IL-10 production in BMDCs ( Fig. 2B) (11) . The EC50 of DCA was much lower than of BRD-6989, driving its subsequent preferential use ( Fig. 2B ). Notably, DCA and BRD-6989 both exhibited low cytotoxicity, even less than that observed with harmine, which we previously identified as one of the least cytotoxic Treg enhancers ( Fig. 2B) (7) . Secondly, we used CRISPR/Cas9 to knock out CDK8 in primary human CD4 + T cells, which led to increased Treg differentiation compared to control cells edited at the IgA locus ( Fig 
DCA-driven Tregs are fully tolerogenic in the absence of innate immune tolerogenic effects.
We next interrogated the suppressive capacity of DCA-driven Treg cells both in vitro and in vivo. Using a standard in vitro suppression assay, we observed no significant differences in the ability of Treg hi -or Treg DCA -driven murine Treg cells to suppress proliferation of co-cultured responder CD4 + T cells ( Figure 3A , red and blue lines respectively). We tested the capacity of DCA-driven Tregs to inhibit inflammation in vivo using a murine model of type 1 diabetes. In this model, transfer of NOD-BDC2.5 + CD4 + T cells, specific for an epitope derived from the islet antigen chromogranin A, into NOD-scid recipients results in islet b-cell destruction and onset of diabetes about 10 days later ( Fig. 3B , black line) (32, 33) . Co-injection of antigen-specific Treg cells, generated from naïve NOD-BDC2.5.Foxp3 IRES-GFP CD4 + T cells using either Treg DCA or Treg hi conditions, significantly and similarly delayed onset of diabetes ( Fig. 3B , blue and red lines respectively) (7) . Finally, we observed similar results in a murine model of intestinal inflammation where transfer of CD45RB hi CD4 + T cells into B10.RAG2 -/recipients resulted in expansion of donor T cells and inflammation most prominent in the colon about 4 weeks later ( Fig. 3C , black line) (34, 35) . Transfer of Treg cells, generated from naïve wild-type C57Bl/6 CD4 + T cells using either Treg DCA or Treg hi conditions, resulted in significant and similar delay of onset of intestinal inflammation (Fig. 3C , blue and red lines respectively) (36) . Together, these results demonstrate that DCA-driven Treg cells are fully functional and equivalent to Treg hi -generated Treg cells both in vitro and in vivo, using model systems employing different genetic backgrounds and T cell specificities. Importantly, these experiments demonstrate that DCA exerts a strong Treg-intrinsic tolerogenic effect in the absence of concomitant effects on the innate immune compartment.
DCA exerts tolerogenic effects on T cell differentiation independently of STAT1/STAT3 Ser727 phosphorylation.
CDK8 phosphorylates STAT1 and STAT3 on Ser727 in several cell types (37) (38) (39) (40) . Although the role of Ser727 phosphorylation in Th1/Th17/Treg differentiation is unknown, its potential contribution is suggested by the central role of STAT1 Tyr701 and STAT3 Tyr705 tyrosine phosphorylation to Th1 and Th17 differentiation respectively (41) (42) (43) . We found that DCA reduced IL-6-driven phosphorylation of STAT3 Ser727 in murine CD4 + T cells ( Fig. 4A ). However, this did not reduce either STAT3 Tyr705 phosphorylation or expression of the key Th17 transcription factor RORgt ( Fig. 4B -C). Total STAT3 protein was only slightly reduced in the context of T cell stimulation ( Fig. 4B ). To definitively test the role of STAT3 Ser727 phosphorylation, we examined the effect of DCA on Th17 differentiation in primary CD4 + T cells from Stat3 Ser727Ala mice, in which Ser727Ala mutation prevents STAT3 Ser727 phosphorylation (38) . Stat3 Ser727Ala CD4 + T cells showed reduced Th17 differentiation, highlighting a novel role of STAT3 Ser727 phosphorylation in this process ( Fig. 4D ). Importantly, DCA similarly suppressed Th17 differentiation in both Stat3 Ser727Ala and wild-type CD4 + T cells, showing that CDK8 inhibition regulates Th17 differentiation independently of regulating STAT3 Ser727 phosphorylation ( Fig. 4D ). DCA similarly enhanced Treg differentiation in both Stat3 Ser727Ala and wild-type CD4 + T cells ( Fig. 4E ). Together, these results demonstrate that DCA regulates Th17 and Treg differentiation independent of STAT3 Ser727 phosphorylation.
Similarly, we found that DCA reduced IFNg-driven phosphorylation of STAT1 on Ser727 but not on Tyr701 in murine CD4 + T cells; total STAT1 protein was unaltered ( Fig. 4F-G) . Expression of the hallmark Th1 transcription factor Tbet was unaltered by DCA except at day 4 ( Fig. 4H ). We examined the effect of DCA on Th1 differentiation in primary CD4 + T cells from Stat1 Ser727Ala mice, in which Ser727Ala mutation prevents STAT1 Ser727 phosphorylation (39) . Stat1 Ser727Ala CD4 + T cells showed reduced Th1 differentiation, highlighting a novel role of STAT1 Ser727 phosphorylation in this process ( Fig. 4I ). Importantly, DCA similarly suppressed Th1 differentiation in both Stat1 Ser727Ala and wild-type CD4 + T cells, showing that CDK8 inhibition regulates Th1 differentiation independently of effects on STAT1 Ser727 phosphorylation ( Fig. 4I ). Additionally, DCA similarly enhanced Treg differentiation in both Stat1 Ser727Ala and wild-type CD4 + T cells ( Fig. 4J ). Together, these results demonstrate that DCA regulates Th1 and Treg differentiation independent of STAT1 Ser727 phosphorylation.
DCA enhances expression of key Treg transcription factors that work through multiple cisregulatory elements.
To better understand how DCA enhances Treg differentiation, we examined the expression of key Treg transcription factors. DCA enhanced the expression of Foxp3, Eos and Helios in murine CD4 + T cells ( Fig. 5A ) (44) (45) (46) . Consistent with the induction of key Treg transcription factors, several other genes were regulated as expected. For example, expression of Cd25 was upregulated while expression of Il2 was downregulated ( Fig. 5A) (47) . This induction of key Treg transcription factors did not involve either enhanced SMAD2/SMAD3 phosphorylation and mTOR inhibition, implying the involvement of novel pathway(s) (Supplemental Fig. 2A-B ). Next, to better understand the cis-regulatory elements most important for DCA-mediated FOXP3 enhancement, we examined mice lacking the key regulatory elements of the Foxp3 locus, CNS1, CNS2 and CNS3 (48) . TGFb titration studies revealed cell-intrinsic roles for all three CNS elements in Treg differentiation in vitro, with CNS 1 ≅ CNS2 > CNS3 ( Fig. 5B ). DCA enhanced Treg differentiation in cells lacking CNS1, CNS2 or CNS3, although not to the same extent as wildtype CD4 + T cells, and suggested a relative contribution of CNS1 > CNS2 > CNS3 ( Fig. 5B and Supplemental Fig. 2C ). These results support a mixed model where all three cis-acting elements, particularly CNS1, participate in DCA-regulated mechanisms.
DCA enhances AP-1 activity and early Foxp3 expression. Temporal analysis of FOXP3
expression throughout the period of culture revealed indistinguishable kinetics between Treg low and Treg hi conditions until day 2, with FOXP3 + cells subsequently increasing in Treg hi conditions and decreasing in Treg low conditions ( Fig. 6A) (7) . Notably, DCA significantly increased FOXP3 + cells until day 2, compared to either Treg low or Treg hi conditions (Fig. 6A ). These data suggest that DCA promotes Treg differentiation at least in part by enhancing early expression of FOXP3 and point to the value of including earlier time points in mechanistic analyses of DCA.
To generate an unbiased understanding of how DCA impacts the Treg transcriptional landscape across time, we cultured Foxp3 GFP CD4 + T cells in Treg low , Treg hi and Treg DCA conditions, and profiled naïve CD4 + T cells, sorted GFP + and GFPcells at day 2 (all conditions) and sorted GFP + Tregs at day 4 (Treg hi and Treg DCA conditions)( Fig. 6A ). The largest determinants of variation revealed by principal component (PC) analyses related to T cell activation (PC1, 46.1% of variation) and the mature Treg program (PC2, 18.9% of variation)( Fig. 6B) . A small but consistent DCA-related signature was detected in the fourth PC, accounting for 4.1% of variation ( Fig. 6C ). Compared to the dearth of differentially expressed genes in either FOXP3 + or FOXP3cells cultured in Treg low or Treg hi conditions at day 2, DCA treatment detectably, if modestly, altered the transcriptional landscape in all cells examined at day 2 and day 4 (6D and Supplemental Fig.  3 ). As CDK8 phosphorylates transcription factors, we reasoned that mechanistic insight might be gleaned from understanding the common transcription factor(s) linking the genes dysregulated by DCA. Transcription factor binding site analysis of the genes perturbed by DCA revealed AP-1 as the only transcription factor consistently enriched in genes impacted by DCA in day 2 FOXP3 -, day 2 FOXP3 + and day 4 FOXP3 + cells (Fig. 6E ). This finding is particularly striking as previous studies have shown that CDK8 inhibition increases AP-1 activity in myeloid cells in part by modulating phosphorylation of the negative regulatory site Ser243 on the AP-1 family member c-Jun (11, 17, 18) . Our interrogation of c-Jun in T cells revealed robust and similar induction of phosphorylation on both Ser243 and Ser63 upon stimulation in either Treg low or Treg hi conditions (Fig. 6F ). Interestingly, DCA significantly reduced c-Jun phosphorylation on the negative regulatory site Ser243, without significantly affecting phosphorylation on the activating site Ser63 (Fig. 6F) . These results imply that CDK8 inhibition promotes Treg differentiation at least in part by modulating c-Jun Ser243 phosphorylation.
Discussion
Here we demonstrate that DCA exerts broad and previously unappreciated tolerogenic effects on CD4 + T cells, promoting differentiation of Treg and Th2 cells, while inhibiting Th1 and Th17 differentiation. Therefore, DCA promotes type 2 and anti-inflammatory immune responses while inhibiting type 1 immune responses. Our use of both novel small molecules (DCA and BRD-6989) and CRISPR/Cas9-mediated deletion point to CDK8 inhibition as the mechanism by which DCA exerts these effects. In conjunction with our previous findings that DCA enhances IL-10 production in myeloid cells, our current data highlight DCA's profile of immunoregulatory activity as distinct from that induced by SIK-and DYRK1A-inhibitors, which exert tolerogenic effects specifically in either innate or adaptive immune cells, but not both (7, 11) . These distinct chemical immunotypes point to an important way to classify both probe molecules and drugs, that could inform about potential side effects as well as suggest shared mechanistic pathways, thus guiding both selection of synergistic therapies and precision medicine approaches. Given that CDK8 inhibition exerts anti-inflammatory effects in both adaptive and innate immune cells, it is tempting to speculate that CDK8 regulates evolutionarily older pathways of tolerogenicity conserved between adaptive and innate immunity.
The translational relevance of these data is reinforced by our finding that DCA promotes Treg differentiation in primary human CD4 + T cells. We note that Tregs generated using DCA are fully functional in vitro and in vivo. Importantly, our use of Treg-transfer models specifically interrogates the functionality of DCA-driven Tregs and avoids confounding immunomodulatory effects of DCA-mediated CDK8 inhibition on other cell types, including innate immune cells, that could confound the interpretation of models using systemic drug administration (22, 23) . These studies have implications for the anticipated clinical use of CDK8 inhibitors as cancer therapeutics, driven by findings that CDK8 can act as a proto-oncogene (49, 50) . The broad tolerogenic effects of DCA may impair host-versus-tumor effects and warrant combination therapy with pro-inflammatory agents. Alternatively, DCA and other CDK8 inhibitors may find utility as tolerogenic immunomodulators. Studies suggesting poor long-term tolerability of CDK8 inhibitors, together with our data showing DCA impacts early pathways in Treg differentiation, support this consideration (51) . Importantly, we recognize the utility of DCA in generating Tregs ex vivo, which would circumvent concerns regarding toxicity in vivo (51) .
Our studies reveal a novel and unexpected property of DCA enhancing expression of FOXP3 and many FOXP3-regulated genes at early timepoints, with FOXP3 expression at later timepoints decaying at a rate similar to that seen in Treg low conditions. These kinetics of FOXP3 expression are distinct from those observed with Treg hi conditions, where early FOXP3 expression is identical to that observed in Treg low conditions with continued increase in FOXP3 + cells at later timepoints. This suggests a model of Treg differentiation that involves independently regulated early and late pathways. Whereas early pathways might involve TGFb licensing cells to adopt Treg fate and express FOXP3, later pathways might center on maintaining Treg lineage commitment. Our data support a model where DCA enhances early pathways regulating FOXP3 expression. This suggests particular therapeutic relevance to patients who have corresponding defects in early pathways of Treg differentiation and also raises the possibility of broader tolerogenic utility when used in conjunction with synergistic therapies that enhance late pathways of Treg differentiation.
Our expression profiling studies support that DCA enhances early expression of FOXP3 be regulating AP-1 transcription factors such as c-Jun. Our data demonstrate that DCA specifically reduced phosphorylation of the inhibitory Ser243 of c-Jun. This is in line with previous finding that CDK8 regulates c-Jun Ser243 in myeloid cells (11) . Our data supports a role for multiple FOXP3 enhancer elements (CNS1, CNS2 and CNS3) in CDK8-regulated expression of FOXP3, suggesting that CDK8 may be recruited to the FOXP3 promoter together with the Mediator complex, subsequently regulating Foxp3 expression at least in part by phosphorylating c-Jun.
Our findings highlight some of the opportunities and challenges that accompany mechanistic dissection of small molecules in T cell biology. Prior knowledge that CDK8 phosphorylates STAT proteins, which play essential roles in T cell differentiation, suggest CDK8-STAT interactions as prime candidates to explain how CDK8 inhibition regulates T cell differentiation (16) . Our experiments using Stat1 Ser727Ala and Stat3 Ser727Ala mice clearly demonstrate that CDK8 regulates Th1, Th17 and Treg differentiation independent of STAT1/STAT3 Ser727 phosphorylation. Prior studies suggest that STAT1 Ser727 /STAT3 Ser727 phosphorylation is required for full transcriptional activity (37) (38) (39) (40) . Consistent with this, we demonstrate a novel role of STAT1 Ser727 and STAT3 Ser727 phosphorylation in regulating Th1 and Th17 differentiation, identifying this as a new potential therapeutic target in T cells.
Recent studies identify AS2863619 and CCT251921 as CDK8/19 inhibitors that enhance Treg differentiation (22, 23) . Our findings that DCA and BRD-6989 enhance Treg differentiation are important not only because they identify additional CDK8/19 inhibitors with similar effects, but also because recent studies point to DCA as having higher specificity and lower toxicity (24) . Our studies here show important novel aspects. First, we show that DCA enhances Th2 differentiation. Second, we demonstrate that DCA enhances human Treg differentiation. Third, we highlight mechanistic considerations. We do not see differences in SMAD2/SMAD3 phosphorylation, contrary to Guo et al (22) . Whether this is due to compound-specific differences remains to be clarified. Further, our findings show that CDK8-regulated phosphorylation of STAT proteins does not necessarily drive effects on T cell differentiation, pointing to the need to develop STAT5 Ser-Ala mutants to test the role of CDK8-regulated STAT5 phosphorylation advocated by Akamatsu et al (23) . Our data demonstrate clearly that DCA enhances early FOXP3 expression. Our data argue for a role of c-Jun, further interrogation of which is of future interest. Fourth, we do not see increased suppressive activity of CDK8 inhibitor-enhanced Tregs, using either DCA or BRD6989 reported by Guo et al (22) . Finally, our use of Treg-transfer models definitively demonstrate Treg-intrinsic effects of DCA in the absence of confounding tolerogenic effects on other cells, including innate immune cells.
In summary, our studies highlight DCA as a novel, human-relevant immunomodulator with potent tolerogenic effects in both innate and adaptive immune cells. DCA's unusual chemical immunophenotype has important mechanistic and therapeutic implications. Our demonstration that DCA effectively enhances Treg differentiation compared to canonical Treg enhancers suggests utility in approaches to generate Tregs ex vivo for adoptive cellular therapy. In addition, the broadly tolerogenic effects of DCA suggest that it may broadly be useful in the setting of pathologic inflammation or autoimmunity.
Mice and Reagents
Balb/c, C57Bl/6, Foxp3 IRES-GFP , CD45.1 +/+ , NOD-scid and NOD-BDC2.5 mice were purchased from Jackson Labs. NOD-BDC2.5.Foxp3 IRES-GFP mice were from the JDRF Transgenic Core (Harvard Medical School, Boston, MA). C57Bl/10-Rag2 −/− mice were a kind gift from Brian Kelsall (35) .
Stat1 Ser727Ala , Stat3 Ser727Ala , Foxp3 DCNS1-gfp , Foxp3 DCNS2-gfp and Foxp3 DCNS3-gfp mice were previously described (38, 39, 48) . Δ16-cortistatin A (DCA) was a generous gift from P. Baran (The Scripps Research Institute) and synthesized as previously reported (9, 52) . Small-molecule reagents were confirmed to have ≥95% purity by HPLC-MS. Antibodies, cytokines, and chemical compounds used are listed in Supplementary file 1.
Murine T cell isolation and culture
Unless otherwise noted, CD4 + CD62L + naïve T cells were isolated from 8-12 week old mice using CD4 negative enrichment kits (Stemcell Technologies, Vancouver, Canada) and CD62L microbeads (Miltenyi Biotec, San Diego, CA) according to the manufacturer's instructions and confirmed >90% pure by flow cytometry. Cells were cultured on 96 well plates pre-coated with anti-CD3 and anti-CD28 using conditions outlined in Supplementary file 2. The addition of DCA to Treg low conditions is abbreviated as Treg DCA . Treg and Th1 cultures were fed with equal volume of IL-2 supplemented media (20ng/ml) and retreated with compound at day 2, split 1:2 into IL-2-supplemented media (10 ng/ml) at day 3 and analyzed at day 4. Th17 cultures were treated similarly except no IL-2 was supplemented. Th2 cultures were treated similarly as Treg cultures except they were additionally split 1:2 into IL-2 supplemented media (10 ng/ml) at day 4 and day 5 and analyzed on day 6.
Human T cell isolation and culture
Frozen PBMCs and fresh peripheral blood samples were obtained from the Benaroya Research Institute Immune Mediated Disease Registry and Repository. Human peripheral blood mononuclear cells were isolated from fresh whole blood by Ficoll-Paque (GE Healthcare, Little Chalfont, United Kingdom). CD4 + CD45RA + naïve T cells were isolated using negative enrichment kits (Stemcell Technologies, Vancouver, Canada) per manufacturer's instructions and confirmed >90% pure by flow cytometry. Cells were cultured on 96 well plates pre-coated with anti-CD3 and anti-CD28 using conditions outlined in Supplementary file 2. Treg cultures were fed with equal volume of IL-2 supplemented media (20ng/ml) and retreated with compound at day 2, split 1:2 into IL-2-supplemented media (10 ng/ml) at day 4 and analyzed at day 5.
Flow Cytometry
Cells were stimulated with PMA and ionomycin (50 and 500ng/ml respectively) (Sigma Aldrich, St. Louis, MO) in the presence of Golgistop (BD Biosciences, San Jose, CA) 5 hours prior to analysis as necessary. Cells were typically stained with LIVE/DEAD and anti-CD4 prior to fixation and permeabilization, which was generally performed with either Foxp3 fixation/permeabilization buffers (eBioscience, San Diego, CA). Phosflow cell lyse/fix and PermIII buffers (BD Biosciences, San Jose, CA) were used for phospho-protein assessment. Intracellular staining was performed per manufacturer's instructions. Counting beads (10 μm, Spherotech, Lake Forest, IL) were added at 5000 per sample. Acquisition was performed on either a FACScalibur or a FACScanto (BD Biosciences, San Jose, CA). Cell sorting was performed using a FACs Aria II (BD Biosciences, San Jose, CA). Data was analyzed using FlowJo software (Treestar, Ashland, OR). Fractional maximal enhancement was determined by increase in percentage lineage-committed cells, relative to maximal cytokine-driven enhancement as previously reported (7) . Fractional inhibition was calculated relative to DMSO treated cells (7) . STAT1/STAT3 phosphorylation was quantified as previously described (53) .
Enzyme-linked immunosorbent assays
IL-2 and IL-10 were detected by sandwich ELISA per manufacturer's protocol (Biolegend, San Diego, CA). Quantitation was based on absorbance at 450 nm, read on a Versamax micro-plate reader (Molecular Devices, San Jose, CA). Samples were run in triplicate.
RNP complexing
RNPs were generated by mixing a 1:2 ratio of Cas9 protein (Aldeverion, Fargo, ND) and sgRNA (Synthego, Menlo Park, CA) with gentle swirling, and incubating at 37°C for 15 minutes. Guides used were IGHA1/2: GAAGACCUUGGGGCUGG; CDK8: CUCAUGCUGAUAGGAAG.
CRISPR-Cas9 gene editing
CRISPR-Cas9 gene editing was performed as previously described (54) . Briefly, human CD4 + CD45RA + naïve T cells were cultured on 96 well plates pre-coated with anti-CD3 and anti-CD28 in Xvivo 15 (Lonza, Basel, Switzerland) supplemented with 5% Fetal Bovine Serum, 50 mM 2-mercaptoethanol (Thermo Fisher, Waltham, MA), 10 mM N-Acetyl L-Cystine (Cayman Chemical, Ann Arbor, MI), 20 ng/ml IL-2 and 2 µg/ml each of anti-IL-12, anti-IFNg and anti-Il-4. Cells were harvested 2 days later, centrifuged (90 g for 8 minutes), resuspended in buffer T, mixed with 20µM RNP and electroporated (1400 volts, 10 ms, 3 pulses) using a Neon transfection system (Thermo Fisher, Waltham, MA). Cells were transferred into 90 µl Opti-MEM (Thermo Fisher, Waltham, MA) pre-warmed to 37°C. After 24 hours, cells were fed with media supplemented with 100 ng/ml IL-2 and 1 ng/ml TGFb. Cells were maintained for 5 additional days at a density of 1x10 6 /ml and then analyzed by flow cytometry.
In vitro proliferation and Treg suppression assay
These were performed as previously described (55) . Briefly, sorted CD45.1 + CD4 + CD62L + Tresponders were labeled with CellTrace Far Red (Thermo Fisher, Waltham, MA) per manufacturer's protocol and plated at 5x10 4 cells per well in 96-well U-bottom plates in the presence of anti-CD3 anti-CD28 beads (Dynabead, Grand Island, NY). For Treg suppression assays, Tresponders were co-cultured with sorted CD45.2 + Foxp3 IRES-GFP+ Treg cells generated as indicated. Cells were analyzed by flow cytometry 3 days later.
Treg suppression -Type 1 diabetes model
These were performed as previously described (7) . Briefly, 5x10 4 sorted CD4 + CD62L + naïve T cells isolated from NOD-BDC2.5 + mice were injected intravenously into NOD-scid mice with or without 1x10 5 Treg cells generated from NOD-BDC2.5 + FOXP3 IRES-GFP mice as indicated (32, 33) . Blood glucose levels were monitored with a handheld Contour glucometer (Bayer, Leverkusen, Germany) at days 3, 6, 8 and every day following. Diabetes was diagnosed when blood sugar exceeded 250 mg/dl for 2 consecutive days.
Treg suppression -CD45RB hi colitis model
As previously described 5x10 5 sorted CD4 + CD62L + naïve T cells isolated from CD45.1 + mice were injected intravenously into B10-Rag2 -/-mice (35, 36) . 5 days later, mice were injected with either PBS or 1.5x10 5 Treg cells generated from Foxp3 IRES-GFP mice as indicated (36) . Mice were monitored at least weekly for weight loss and morbidity per protocol. Mice were euthanized after 4 weeks and proximal, medial, and distal colon analyzed histologically by blinded observers as previously described (56) .
Histology
Tissues were preserved in 10% formalin. Paraffin embedding, sectioning and staining with hematoxylin and eosin was performed by the Histology Core (Benaroya Research Institute, Seattle, WA). Fractions were subsequently lysed with Triton X-100 lysis buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl pH7.8). Band intensity was quantified by ImageJ (57) . Antibodies are listed in Supplementary File 1.
Western Blotting
RNA Isolation and qRT-PCR
RNA was isolated using RNeasy kits (Qiagen, Valencia, CA) and cDNA generated using iScript cDNA synthesis kits (BioRad, Hercules, CA) per manufacturer's directions. Real-time PCR was performed using an ABI 7500 FAST REAL-TIME PCR (Applied Biosystems, Foster City, CA) system. Cycling conditions were as follows; 1 cycle of 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute. Primers used were Il17: TTTAACTCCCTTGGCGCAAAA and CTTTCCCTCCGCATTGACAC; Il22: CATGCAGGAGGTGGTACCTT and CAGACGCAAGCATTTCTCAG; Batf: GACACAGAAAGCCGACACC and AGCACAGGGGCTCGTG; Pou2af1: CACCAAGGCCATACCAGGG and GAAGCAGAAACCTCCATGTCA; Mina: TTTGGGTCCTTAGTAGGCTCG and CCGATCCGGTCCTCAGATT; Foxp3: GGCCCTTCTCCAGGACAGA and GCTGATCATGGCTGGGTTGT; Ikzf2: TCACAACTATCTCCAGAATGTCAGC and AGGCGGTACATGGTGACTCAT; Ikzf4: CGGCATCCGGCTACCCAACG and AGGTCACGGATTTCATCACCTGGC; Il2ra: CCACATTCAAAGCCCTCTCCTA and GTTTTCCCACACTTCATCTTGC; Il-2: TTGTGCTCCTTGTCAACAGC and CTGGGGAGTTTCAGGTTCCT; Ctla4: ACTCATGTACCCACCGCCATA and GGGCATGGTTCTGGATCAAT; CDK8: GACTATCAGCGTTCCAATCCAC and TAGCTGAGTATCCCATGCTGC. b-ACTIN:
CACCATTGGCAATGAGCGGTTC and AGGTCTTTGCGGATGTCCACGT; RPS18: TCATCCTCCGTGAGTTCTCCA and AGTTCCAGCACATTTTGCGAG.
RNA-seq library preparation and sequencing
RNA-seq libraries were generated from four Foxp3 GFP littermate mice. On day 0, 1000 naïve CD4 + CD62L + cells were sorted for RNA-seq. The remaining cells were cultured on plates precoated with anti-CD3 and anti-CD28 in Treg low , Treg hi and Treg DCA conditions. On day 2, 250 FOXP3 + cells and 500 FOXP3cells were sorted from cells cultured in Treg low , Treg hi and Treg DCA conditions. On day 4, 1000 FOXP3 + cells were sorted from Treg hi and Treg DCA cultures. Cells were sorted directly into lysis buffer from the SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing (Takara) and frozen until all samples were ready for simultaneous processing. Reverse transcription was performed followed by PCR amplification to generate full length amplified cDNA. Sequencing libraries were constructed using the NexteraXT DNA sample preparation kit (Illumina) to generate Illumina-compatible barcoded libraries. Libraries were pooled and quantified using a Qubit® Fluorometer (Life Technologies). Dual-index, single-read sequencing of pooled libraries was carried out on a HiSeq2500 sequencer (Illumina) with 58-base reads, using HiSeq v4 Cluster and SBS kits (Illumina) with a target depth of 5 million reads per sample.
Base-calling was performed automatically by Illumina real time analysis software. Demultiplexing to generate FASTQ files was performed by bcl2fastq running on the Illumina BaseSpace platform. Subsequent processing was performed using the Galaxy platform. FASTQ reads were trimmed in two steps: 1) hard-trimming to remove 1 3'-end base (FASTQ Trimmer tool, v.1.0.0); 2) quality trimming from both ends until minimum base quality for each read ≥ 30 (FastqMcf, v.1.1.2). Reads were aligned to the GRCm38 mouse reference genome using STAR v.2.4.2a, with gene annotations from GRCm38 Ensembl release number 91. Read counts per Ensembl gene ID were quantified using htseq-count v.0.4.1. Sequencing, alignment, and quantitation metrics were obtained for FASTQ, BAM/SAM, and count files in Galaxy using FastQC v0.11.3, Picard v1.128, Samtools v1.2, and htseq-count v.0.4.1. The raw RNA-seq data has been deposited to the Gene Expression Omnibus (GEO) with accession numbers []
PCA and Correlation Analysis
All analysis of RNA-seq data was performed in the R programming language and Rstudio environment (58) (59) (60) . One library (Treg hi day 2 GFP + ) was excluded from downstream analysis due to low read quality. The libraries were normalized as a single batch via TMM normalization and the genes were filtered to include only those genes classified as protein coding by Ensembl gene annotations with ≥ 5 normalized counts in ≥ 10% of the 36 libraries analyzed. Principal component analysis (PCA) was performed using the counts of the filtered gene set. Differentially expressed genes were identified using lmfits and voom WithQualityWeights from the limma package with thresholds of log2 fold change ≥ 1.5 and FDR adjusted p-value ≤ 0.05.
The R code for all analyses performed in this manuscript has been annotated and deposited as open-source code in GitHub at []
Pathway Analysis
Pathway analysis was performed using the Gene Set Enrichment Analysis Molecular Signature Database or MSigDB v7.0 which uses the hypergeometric distribution on a background of all genes to calculate a p-value (61-63).
Statistical analyses
Statistical measures, including mean values, standard deviations, Student's t-tests, Mantel-Cox tests, Mann-Whitney tests and one-way ANOVA tests, were performed using Graphpad Prism software and R. Where appropriate, unless otherwise stated, graphs display mean ± standard deviation.
Study approval
All murine experiments were performed with the approval of the IACUC of Benaroya Research Institute (Seattle, WA). Human studies were approved by the Benaroya Research Institute's Institutional Review Board and all subjects signed written informed consent prior to inclusion in the study. 
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